CoSyne Therapeutics is a drug discovery company and spin-out from academic research at Imperial College London. It was founded in 2021 by experts in neuroscience, genetics and computational analysis.
CoSyne Therapeutics is using genetic computational systems analysis to develop next generation medicines at a faster rate, and for lower cost, compared to traditional methods.
The company’s first goal is to create a new class of drugs to treat the deadliest form of human brain cancer: Glioblastoma Multiforme.
The CoSyne Therapeutics platform has already identified dozens of novel vulnerabilities in GBM that can be targeted in a way that no other company or academic institution has done before.
Glioblastoma Multiforme (GBM)
“Brain tumours are awful things – they not only steal lives, they steal everything you are as a person.”
From a patient with glioblastoma multiforme.